Sanofi/Medco-UBC Evidence Partnership Includes 60 Projects Across Most Therapeutic Categories
Executive Summary
Projects include creation of an enhanced “core value dossier” supporting reimbursement for a novel oncology drug and development of a “relative medical value index” framework to help prioritize pipeline projects and highlight opportunities to expand an individual drug study plan to address payer needs.
You may also be interested in...
Express Scripts Realignment Identifies Non-Core Businesses
Express Scripts is “looking at strategic alternatives” for some of its non-core businesses, which include international ventures, UBC and PolyMedica.
Incyte’s Jakafi Gets Additional Claim Based On Patient-Reported Outcomes
Jakafi is the first approved treatment for myelofibrosis, a rare bone marrow cancer, but Incyte will also be able to claim efficacy against the symptoms of the disease thanks to data in labeling from a patient-reported outcomes tool.